With “Bringing Laboratory Testing to the Home,” DRIVe is seeking disruptive platform technologies to serve as reliable alternatives to traditional central laboratory testing. During COVID-19, the U.S. experienced a surge in telemedicine utilization, yet most routine testing still required visits to an office, clinic, or lab. At-home testing platforms could enhance the capabilities of telemedicine by enabling data-driven diagnosis by healthcare providers without requiring sample shipping or travel to a sample collection site. If successful, a full suite of at-home testing could revolutionize diagnostics, chronic disease management, and even clinical research, providing better access to care and a more disaster-resilient health care system. DRIVe is seeking proposals for multiplexed biochemical assays that can be performed at home, without requiring special training or access to a full laboratory.
Improved medical services and health outcomes – enhanced through sample collection and testing in the convenience of the patient’s home.
To support the development and validation of new platform technologies for simple, rapid multiplexed analysis of biological specimens in the home setting – run by the patient, interpreted by the MD.